Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/4947
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Murnane, Pamela M. | - |
dc.contributor.author | Brown, Elizabeth R. | - |
dc.contributor.author | Mugo, Nelly | - |
dc.contributor.author | Mujugira, Andrew | - |
dc.contributor.author | Celum, Connie | - |
dc.contributor.author | Baeten, Jared M. | - |
dc.contributor.author | Were, Edwin | - |
dc.contributor.author | Bukusi, Elizabeth | - |
dc.contributor.author | Wangisi, Jonathan | - |
dc.contributor.author | Kiarie, James | - |
dc.date.accessioned | 2021-07-27T11:57:33Z | - |
dc.date.available | 2021-07-27T11:57:33Z | - |
dc.date.issued | 2015 | - |
dc.identifier.uri | https://doi.org/10.1093/aje/kwv202 | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/4947 | - |
dc.description.abstract | Antiretroviral pre exposure prophylaxis (PrEP) for persons at high risk of human immunodeficiency virus infection is a promising new prevention strategy. Six randomized trials of oral PrEP were recently conducted and demonstrated efficacy estimates ranging from 75% to no effect, with non adherence likely resulting in attenuated estimates of the protective effect of PrEP. In 1 of these trials, the Partners PrEP Study (Kenya and Uganda, 2008–2011), participants (4,747 serodiscordant heterosexual couples) were randomized to receipt of tenofovir (TDF), coformulated TDF/emtricitabine (FTC), or placebo. Intention-to-treat analyses found efficacy estimates of 67% for TDF and 75% for TDF/FTC. We applied multiple methods to data from that trial to estimate the efficacy of PrEP with high adherence, including principal stratification and inverse-probability-of-censoring (IPC) weights. Results were further from the null when correcting for nonadherence: 1) among the strata with an estimated 100% probability of high adherence (TDF hazard ratio (HR) = 0.19, 95% confidence interval (CI): 0.07, 0.56; TDF/FTC HR = 0.12, 95% CI: 0.03, 0.52); 2) with IPC weights used to approximate a continuously adherent population (TDF HR = 0.18, 95% CI: 0.06, 0.53; TDF/FTC HR = 0.15, 95% CI: 0.04, 0.52); and 3) in per-protocol analysis (TDF HR = 0.18, 95% CI: 0.06, 0.53; TDF/FTC HR = 0.16, 95% CI: 0.05, 0.53). Our results suggest that the efficacy of PrEP with high adherence is over 80%. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Oxford University Press | en_US |
dc.subject | Pre exposure prophylaxis | en_US |
dc.subject | HIV-1 prevention | en_US |
dc.subject | Randomized controlled trials | en_US |
dc.subject | Medication adherence | en_US |
dc.title | Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.